These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35134204)

  • 21. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
    Robbins IM; Gaine SP; Schilz R; Tapson VF; Rubin LJ; Loyd JE
    Chest; 2000 Jan; 117(1):14-8. PubMed ID: 10631192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary hypertension on systemic sclerosis-lupus erythematosus overlap syndrome.
    Rachdi I; Tougorti M; Daoud F; Aydi Z; Zoubeidi H; Ben Dhaou B; Boussema F
    Ann Cardiol Angeiol (Paris); 2019 Oct; 68(4):221-225. PubMed ID: 30685083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
    Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
    Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
    Jiménez A; Ais A; Beaudet A; Gil A
    Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus-pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan.
    Atsumi T; Tan JY; Chiang AP; Yu DY; Makanji Y; Wu DB; Casorso J; Kouhkamari M; Lim S
    Mod Rheumatol; 2024 Jul; 34(4):741-749. PubMed ID: 37747781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Could pulmonary arterial hypertension be an active index of systemic lupus erythematosus? A successful case of SLE-PAH cured by methylprednisolone pulse therapy.
    Huang C; Zhang S; Tian Z; Li M; Zeng X
    Lupus; 2014 Dec; 23(14):1533-6. PubMed ID: 25260565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe pulmonary arterial hypertension secondary to lupus in the emergency department: proactive intense care associated with a better short-term survival.
    Chen Y; Guo L; Li Y; Chen GL; Chen XX; Ye S
    Int J Rheum Dis; 2015 Mar; 18(3):331-5. PubMed ID: 24946184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment of pulmonary hypertension with aerosolized iloprost.
    Machherndl S; Kneussl M; Baumgartner H; Schneider B; Petkov V; Schenk P; Lang IM
    Eur Respir J; 2001 Jan; 17(1):8-13. PubMed ID: 11307761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients.
    Donnarumma JFS; Ferreira EVM; Ota-Arakaki J; Kayser C
    Adv Rheumatol; 2019 Jan; 59(1):1. PubMed ID: 30657102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
    Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbruck B; Grimminger F; Seeger W
    Am J Respir Crit Care Med; 1999 Aug; 160(2):600-7. PubMed ID: 10430735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
    Ding Y; Qian J; Zhang S; Xu D; Leng X; Zhao J; Wang Q; Zhang W; Tian X; Li M; Zeng X
    Int J Rheum Dis; 2022 Sep; 25(9):982-990. PubMed ID: 35699128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment.
    Petkov V; Ziesche R; Mosgoeller W; Schenk P; Vonbank K; Stiebellehner L; Raderer M; Brunner C; Kneussl M; Block LH
    Thorax; 2001 Sep; 56(9):734-6. PubMed ID: 11514696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.